{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:35:11Z","timestamp":1790994911173,"version":"4.1.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Mental disorders represent a significant global burden, with a high proportion of depressive disorders. Antidepressants (ADs) are the most prescribed drugs for treating mental disorders, with broad indications, e.g. depression, anxiety disorders, and off-label use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study assesses current and historical changes in AD consumption in 25 European countries, predicts future developments, and further analyses ATC subgroup consumption in 13 countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Consumption data for ADs (ATC code N06A) were collected from the OECD Data Explorer. Subgroup data came from publicly available sources. The time span covered is 1980 to 2024. Changes in defined daily doses per 1000 population per day (DID) were analysed, and projections to 2030 were made using Auto Regressive Integrated Moving Average models. Treatment coverage for depressive disorder prevalence was also calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2023, AD consumption ranged from 26.3 DID (Latvia) to 164.7 DID (Iceland). Use increased in nearly all countries, except Luxembourg (\u2212\u20090.3 DID between 2013 and 2022). Increases ranged from\u2009+\u20095.9% (Austria) to\u2009+\u2009157.8% (Latvia). Forecasts predict further increases in most countries (+\u20090.1 to\u2009+\u200980.9%), with decreases projected for Hungary, Austria, the UK, and Luxembourg (\u2212\u20093.4 to \u2212\u200921.7%). Selective serotonin reuptake inhibitors (SSRIs) are the most used subgroup, with mixed developments. The second most used is miscellaneous, with growing shares in most countries. Non-selective monoamine reuptake inhibitors (NSMRIs) are declining, while monoamine oxidase inhibitors (MAO-Is) and monoamine oxidase A inhibitors (MAOA-Is) have very low shares. Northern Europe shows the highest AD use versus Eastern Europe the lowest. All regions primarily use SSRIs. Northern Europe has a higher miscellaneous share, while Eastern Europe uses more NSMRIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AD use has increased and is projected to continue rising in most countries, with changing subgroup preferences. The dominance of SSRIs reflects first-line treatment recommendations. Increased miscellaneous use may indicate more individualised treatment and better tolerability. NSMRIs are declining due to adverse effects, and MAO-Is as well as MAOA-Is are rarely used due to safety concerns. Prescribing patterns vary across regions, influenced by health systems, cultural differences, stigma, and healthcare resources.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-025-02078-9","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:41:20Z","timestamp":1773121280000},"page":"819-833","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antidepressant drug use in Europe: past consumption, prescribing patterns and forecast until 2030"],"prefix":"10.1007","volume":"48","author":[{"given":"Lilly Josephine","family":"Bindel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"2078_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jpsychires.2019.08.002","volume":"126","author":"Q Liu","year":"2020","unstructured":"Liu Q, He H, Yang J, Fengf X, et al. Changes in the global burden of depression from 1990 to 2017: findings from the Global Burden of Disease study. J Psychiatric Res. 2020;126:134\u201340. https:\/\/doi.org\/10.1016\/j.jpsychires.2019.08.002.","journal-title":"J Psychiatric Res"},{"key":"2078_CR2","unstructured":"Pan American Health Organization (PAHO). World Mental Health Day: Depression, the Most Common Mental Disorder. News. PAHO 2012. 2012. https:\/\/www.paho.org\/en\/news\/9-10-2012-world-mental-health-day-depression-most-common-mental-disorder. Accessed 9 Apr 2025."},{"key":"2078_CR3","unstructured":"Our World in Data. Mental illness prevalence, World, 2021. Data source: IHME, Global Burden of Disease. 2024. https:\/\/ourworldindata.org\/grapher\/mental-illnesses-prevalence. Accessed 13 Apr 2025."},{"issue":"3\u20134","key":"2078_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00508-018-1316-1","volume":"130","author":"A \u0141aszewska","year":"2018","unstructured":"\u0141aszewska A, \u00d6sterle A, Wancata J, et al. Prevalence of mental diseases in Austria\u202f: systematic review of the published evidence. Wien Klin Wochenschr. 2018;130(3\u20134):141\u201350. https:\/\/doi.org\/10.1007\/s00508-018-1316-1.","journal-title":"Wien Klin Wochenschr"},{"key":"2078_CR5","unstructured":"Our World in Data. Burden of disease from each category of mental illness, World, 2021. Data source: IHME, Global Burden of Disease. 2024. https:\/\/ourworldindata.org\/grapher\/burden-disease-from-each-mental-illness. Accessed 13 Apr 2025."},{"key":"2078_CR6","volume-title":"Arzneiverordnungs-report 2023","author":"W Ludwig","year":"2024","unstructured":"Ludwig W, M\u00fchlbauer M, Seifert R. Arzneiverordnungs-report 2023. 1st ed. Berlin, Heidelberg: Springer; 2024.","edition":"1"},{"key":"2078_CR7","unstructured":"Sheffler ZM, Patel P, Abdijadid S. Antidepressants. Statpearls Publishing 2023, Treasure Island (FL). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538182\/"},{"key":"2078_CR8","doi-asserted-by":"publisher","first-page":"117863292412825","DOI":"10.1177\/11786329241282526","volume":"17","author":"M Martella","year":"2024","unstructured":"Martella M, Minutiello E, Gianino MM. Patterns of antidepressant and anxiolytic use and spending in 14 European countries (2012\u20132021): a comprehensive time series analysis. Health Serv Insights. 2024;17:11786329241282526. https:\/\/doi.org\/10.1177\/11786329241282526.","journal-title":"Health Serv Insights"},{"key":"2078_CR9","doi-asserted-by":"publisher","first-page":"12346","DOI":"10.1038\/s41598-024-62381-9","volume":"14","author":"J Liu","year":"2024","unstructured":"Liu J, Liu Y, Ma W, et al. Temporal and spatial trend analysis of all-cause depression burden based on Global Burden of Disease (GBD) 2019 study. Sci Rep. 2024;14:12346. https:\/\/doi.org\/10.1038\/s41598-024-62381-9.","journal-title":"Sci Rep"},{"issue":"10312","key":"2078_CR10","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","volume":"398","author":"DF Santomauro","year":"2021","unstructured":"Santomauro DF, Herrera AM, Shadid J, et al. (COVID-19 Mental Disorders Collaborators). Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. The Lancet. 2021;398(10312):1700\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(21)02143-7.","journal-title":"The Lancet"},{"key":"2078_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-03887-5","author":"LJ Bindel","year":"2025","unstructured":"Bindel LJ, Seifert R. Most European countries will miss EU targets on antibacterial use by 2030: historical analysis of European and OECD countries, comparison of community and hospital sectors and forecast to 2040. Naunyn-Schmiedebergs Arch Pharmacol. 2025. https:\/\/doi.org\/10.1007\/s00210-025-03887-5.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"2078_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04121-y","author":"LJ Bindel","year":"2025","unstructured":"Bindel LJ, Seifert R. Aware classification analysis for European countries with ARIMA forecasts to assess prescribing patterns and \u2018One Health\u2019 targets. Naunyn-Schmiedebergs Arch Pharmacol. 2025. https:\/\/doi.org\/10.1007\/s00210-025-04121-y.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"2078_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-03930-5","author":"LJ Bindel","year":"2025","unstructured":"Bindel LJ, Seifert R. Long-term forecasting and evaluation of medicine consumption for the ATC class H with a focus on thyroid hormones in OECD countries using ARIMA models. Naunyn-Schmiedebergs Arch Pharmacol. 2025. https:\/\/doi.org\/10.1007\/s00210-025-03930-5.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"2078_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04389-0","author":"LJ Bindel","year":"2025","unstructured":"Bindel LJ, Seifert R. Evidence of lithium underuse in bipolar disorder: analysis of lithium and antipsychotic consumption, prediction of future trends, regional disparities and indicators of rational and inappropriate use in Europe. Naunyn-Schmiedebergs Arch Pharmacol. 2025. https:\/\/doi.org\/10.1007\/s00210-025-04389-0.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"2078_CR15","doi-asserted-by":"publisher","first-page":"12124","DOI":"10.1038\/s41598-025-96037-z","volume":"15","author":"M Oscoz-Irurozqui","year":"2025","unstructured":"Oscoz-Irurozqui M, Villani L, Martinelli S, et al. Trend analysis of antidepressant consumption in Italy from 2008 to 2022 in a public health perspective. Sci Rep. 2025;15(1):12124. https:\/\/doi.org\/10.1038\/s41598-025-96037-z.","journal-title":"Sci Rep"},{"issue":"4","key":"2078_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/13651501.2022.2057331","volume":"26","author":"N Cebron Lipovec","year":"2022","unstructured":"Cebron Lipovec N, Anderlic A, Locatelli I. General antidepressants prescribing trends 2009\u20132018 in Slovenia: a cross-sectional retrospective database study. Int J Psychiatry Clin Pract. 2022;26(4):401\u20135. https:\/\/doi.org\/10.1080\/13651501.2022.2057331.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"9","key":"2078_CR17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/pds.1944","volume":"19","author":"LH Arias","year":"2010","unstructured":"Arias LH, Lobato CT, Ortega S, et al. Trends in the consumption of antidepressants in Castilla y Le\u00f3n (Spain). Association between suicide rates and antidepressant drug consumption. Pharmacoepidemiol Drug Saf. 2010;19(9):895\u2013900. https:\/\/doi.org\/10.1002\/pds.1944.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2078_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-33765-0","volume":"13","author":"L Madeira","year":"2023","unstructured":"Madeira L, Queiroz G, Henriques R. Prepandemic psychotropic drug status in Portugal: a nationwide pharmacoepidemiological profile. Sci Rep. 2023;13:6912. https:\/\/doi.org\/10.1038\/s41598-023-33765-0.","journal-title":"Sci Rep"},{"issue":"2","key":"2078_CR19","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.19m02552","volume":"22","author":"AH Heald","year":"2020","unstructured":"Heald AH, Stedman M, Davies M, et al. Antidepressant prescribing in England: patterns and costs. Primary Care Compan CNS Disorders. 2020;22(2):19m02552. https:\/\/doi.org\/10.4088\/PCC.19m02552.","journal-title":"Primary Care Compan CNS Disorders"},{"key":"2078_CR20","unstructured":"World Health Organization (WHO). ATC\/DDD Index. N Nervous system. WHO. 2024. Last accessed: March 31 2025. https:\/\/atcddd.fhi.no\/atc_ddd_index\/?code=N06A&showdescription=no. Accessed 31 Mar 2025."},{"key":"2078_CR21","unstructured":"Organisation for Economic Co-operation and development (OECD). OECD Data Explorer. Pharmaceutical consumption. OECD. 2025. https:\/\/data-viewer.oecd.org\/?chartId=2c0ba8fa-1b08-4694-babf-43ae35b8659e. Accessed 4 Apr 2025."},{"key":"2078_CR22","unstructured":"Vermeylen M, Hans G, Baeyens JP et al. (Comit\u00e9 d\u2019\u00e9valuation des pratiques m\u00e9dicales en mati\u00e8re de m\u00e9dicaments). Tableaux de bord pharmaceutices. D\u00e9livrances pharmaceutiques dans le secteur ambulant 2014. Institut national d'assurance maladie-invalit\u00e9 (INAMI). 2015. https:\/\/www.inami.fgov.be\/SiteCollectionDocuments\/pharma_tableau_de_bord_rapport_2014.pdf. Accessed 25 Mar 2025."},{"key":"2078_CR23","unstructured":"Dragani\u0107 P, \u0160kribulja M, O\u0161tar\u010devi\u0107 S et al. Potro\u0161nja lijekova u Hrvatskoj 2018\u20132022. Agency for Medicinal Products and Medicals Devices (HALMED). 2023. https:\/\/www.halmed.hr\/fdsak3jnFsk1Kfa\/publikacije\/Potrosnja-lijekova-u-Hrvatskoj-2018-2022.pdf. Accessed 25 Mar 2025."},{"key":"2078_CR24","unstructured":"Dragani\u0107 P, \u0160kribulja M, O\u0161tar\u010devi\u0107 S et al. Potro\u0161nja lijekova u Hrvatskoj 2013\u20132017. Agency for Medicinal Products and Medicals Devices (HALMED). 2018. https:\/\/www.halmed.hr\/fdsak3jnFsk1Kfa\/publikacije\/Potrosnja-lijekova-u-Hrvatskoj-2013-2017.pdf. Accessed 25 Mar 2025."},{"key":"2078_CR25","unstructured":"Dragani\u0107 P, \u017de\u017eeli\u0107 S, \u0160arini\u0107 VM et al. Potro\u0161nja lijekova u Hrvatskoj 2007\u20132012. Agency for Medicinal Products and Medicals Devices (HALMED). 2014. https:\/\/www.halmed.hr\/fdsak3jnFsk1Kfa\/publikacije\/Potrosnja_lijekova_u_Hrvatskoj_2007-2012.pdf. Accessed 25 Mar 2025."},{"key":"2078_CR26","unstructured":"Sundhedsdatastyrelsen. Medstat.dk. The Danish Health Data Authority. 2024. Copenhagen. https:\/\/www.medstat.dk\/en. Accessed 25 Mar 2025."},{"key":"2078_CR27","unstructured":"ANDMEBAAS. Statistics on medicines. ATC-N: Nervous system. Health Statistics and Health Research Database. 2025. https:\/\/statistika.tai.ee\/pxweb\/en\/Andmebaas\/Andmebaas__06Ravimistatistika__01Ravimistatistika\/ATC-N.px\/. Accessed 25 Mar 2025."},{"key":"2078_CR28","unstructured":"Savaikis L, Seilis A, Gailite E et al. Baltic statistics on medicines 2016\u20132018. State Medicines Control Agency of Lithuania. 2019. Vilnius, Lithuania. ISBN 978-609-462-139-0. https:\/\/www.zva.gov.lv\/sites\/default\/files\/2020-01\/Baltic%20statistics_3rd%20edition.pdf. Accessed 17 Feb 2025."},{"key":"2078_CR29","unstructured":"Seilis A, Gailite E, Rootslane L et al. Baltic Statistics on Medicines 2013\u20132015. 2nd edition. Latvian State Agency of Medicines 2016. Riga, Latvia. ISBN 978-9934-8602-2-5. https:\/\/www.zva.gov.lv\/sites\/default\/files\/2018-05\/Baltic%20Statistics%20on%20Medicines%202013%20-%202015.pdf. Accessed 17 Feb 2025."},{"key":"2078_CR30","unstructured":"Rootslane L, Laius O, Sepp J et al. Baltic Statistics on Medicines 2010\u20132012. Estonian State Agency of Medicines 2013. Tartu, Estonia. ISBN 978-9949-33-397-4. https:\/\/www.zva.gov.lv\/sites\/default\/files\/2018-05\/BS_2013.pdf. Accessed 18 Feb 2025."},{"key":"2078_CR31","unstructured":"Finnish Medicines Agency (FIMEA). Drug consumption statistics. Drug consumption in years 2018\u20132021. FIMEA. 2021. http:\/\/raportit.nam.fi\/raportit\/kulutus\/laakekulutus_e.html. Accessed 19 Feb 2025."},{"key":"2078_CR32","unstructured":"Wissenschaftliches Institut der AOK (WIdO). PharMaAnalyst. WidO. 2024. https:\/\/arzneimittel.wido.de\/PharMaAnalyst\/?1. Accessed 25 Mar 2025."},{"key":"2078_CR33","unstructured":"Directorate of Health. Lyfjanotkun \u00e1 \u00cdslandi. Eftir ATC flokkunarkerfi lyfja. Directorate of Health 2025. 2025. https:\/\/app.powerbi.com\/view?r=eyJrIjoiZmRiMGJkNmMtZWQ4NC00NmUzLTlkY2UtZTQ0NDk5ZjZmMDE2IiwidCI6Ijc2NGEzMDZkLTBhNjgtNDVhZC05ZjA3LTZmMTgwNDQ0N2NkNCIsImMiOjh9. Accessed 22 Mar 2025."},{"key":"2078_CR34","unstructured":"Italian Medicines Agency. National Report on Medicines Use in Italy. Year 2023. The Medicines Utilisation Monitoring Centre. 2024. Rome. ISBN: 979-12-80335-37-1. https:\/\/www.aifa.gov.it\/documents\/20142\/2594020\/AIFA_Rapporto_OsMed_2023_EN.pdf. Accessed 24 Mar 2025."},{"key":"2078_CR35","unstructured":"Russo P, Cangini A, Fortinguerra F et al. National Report on Medicines Use in Italy. Year 2022. The Medicines Utilisation Monitoring Centre. Rome: Italian Medicines Agency; 2023. ISBN: 979\u201012\u201080335\u201031\u20109. https:\/\/www.aifa.gov.it\/documents\/20142\/2143103\/Rapporto-OsMed-2022_EN.pdf. Accessed 24 Mar 2025."},{"key":"2078_CR36","unstructured":"Cangini A, Fortinguerra F, Pierantozzi A et al. National Report on Medicines Use in Italy. Year 2021. The Medicines Utilisation Monitoring Centre 2022. Rome. Italian Medicines Agency. ISBN: 979\u201012\u201080335\u201026\u20105. https:\/\/www.aifa.gov.it\/documents\/20142\/1740782\/Rapporto-OsMed-2021_EN.pdf. Accessed 24 Mar 2025."},{"key":"2078_CR37","unstructured":"Cangini A, Fortinguerra F, Pierantozzi A et al. National Report on Medicines Use in Italy. Year 2020. The Medicines Utilisation Monitoring Centre 2021. Rome: Italina Medicines Agency; 2021. ISBN: 979-12-80335-17-3. https:\/\/www.aifa.gov.it\/documents\/20142\/1542390\/Rapporto-OsMed-2020_EN.pdf. Accessed 24 Mar 2025."},{"key":"2078_CR38","unstructured":"Trotta F, Traversa G, Altamura G et al. National Report on Medicines Use in Italy. The Medicines Utilisation Monitoring Centre 2020. Rome: Italian Medicines Agency; 2019. ISBN: 979\u00ad12\u00ad80335\u00ad00\u00ad5. https:\/\/www.aifa.gov.it\/documents\/20142\/241052\/OsMed_2019_Eng.pdf. Accessed 24 Mar 2025."},{"key":"2078_CR39","unstructured":"Trotta F, Filippo AD, Vito AD et al. National Report on Medicines Use in Italy. The Medicines Utilisation Monitoring Centre 2020. Rome: Italian Medicines Agency; 2018. https:\/\/www.aifa.gov.it\/documents\/20142\/241052\/OsMed_2018_Eng.pdf. Accessed 22 Mar 2025."},{"key":"2078_CR40","unstructured":"Trotta F, Filippo AD, Vito AD et al. National Report on Medicines Use in Italy. The Medicines Utilisation Monitoring Centre 2019. Rome: Italian Medicines Agency; 2017. https:\/\/www.aifa.gov.it\/documents\/20142\/241052\/OsMed_2017_eng.pdf. Accessed 22 Mar 2025."},{"key":"2078_CR41","unstructured":"Gailite E, Seilis A, Zake A. Statistics on medicines consumption 2012. State Agency of Medicines. 2013. https:\/\/www.zva.gov.lv\/sites\/default\/files\/2018-05\/Zalu_paterina_statistika_2012-20130604.pdf. Accessed 22 Mar 2025."},{"key":"2078_CR42","unstructured":"State Medicines Control Agency of Lithuania. Medicines consumption 2022. State Medicines Control Agency of Lithuania. 2023. https:\/\/vvkt.lrv.lt\/media\/viesa\/saugykla\/2023\/9\/5gjLnBtWc7s.docx. Accessed 23 Mar 2025."},{"key":"2078_CR43","unstructured":"Dutch Healthcare Institute. GIPdatabank.nl. Dutch Healthcare Institute. 2024. https:\/\/www.gipdatabank.nl\/databank?infotype=g&label=00-totaal&tabel=B_01-basis&geg=ddd&item=N. Accessed 23 Mar 2025."},{"key":"2078_CR44","unstructured":"Folkehelseinstituttet. Norwegian Prescription Database. The Norwegian Institute of Public Health. 2021. https:\/\/www.norpd.no\/. Accessed 23 Mar 2025."},{"key":"2078_CR45","unstructured":"Olsen K, Skoufa II, Bakken GV et al. Drug Consumption in Norway 2019\u20132023. Data from Norwegian Drug Wholesales Statistics. Folkehelseinstituttet. The Norwegian Institute of Public Health 2024. Oslo, Norway. ISBN: 978-82-8406-459-8. https:\/\/www.fhi.no\/contentassets\/b0802ad9303347b682cf6a8fa701ec91\/legemiddelforbruket-i-norge-2019-2023-rapport-2024.pdf. Accessed 23 Mar 2025."},{"key":"2078_CR46","unstructured":"Ministerio de Sanidad. Consumo de Productos Farmac\u00e9uticos. Datos de consumo de recetas m\u00e9dicas del SNS seg\u00fan clasificaci\u00f3n Anat\u00f3mica-Terap\u00e9utica-Qu\u00edmica (ATC). Ministerio de Sanidad. 2025. https:\/\/www.sanidad.gob.es\/areas\/farmacia\/consumoMedicamentos\/ATC\/home.htm. Accessed 23 Mar 2025."},{"key":"2078_CR47","unstructured":"Socialstyrelsen. Statistikdatabas f\u00f6r l\u00e4kemedel. Socialstyrelsen. 2025. https:\/\/sdb.socialstyrelsen.se\/if_lak\/val.aspx. Accessed 23 Mar 2025."},{"key":"2078_CR48","unstructured":"STATBEL. Population by place of residence, nationality (Belgian\/non-Belgian), marital status, age and gender. STATBEL. 2024. Last accessed: March 26 2025. https:\/\/bestat.statbel.fgov.be\/bestat\/crosstable.xhtml?view=1b9e219b-0387-4a70-880a-dc5eccaa244c. Accessed 26 Mar 2025."},{"key":"2078_CR49","unstructured":"Eurostat. Database. Population (national level). European Union. Eurostat. 2025. https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/tps00001\/default\/table?lang=en&category=t_reg.t_reg_dem. Accessed 26 Mar 2025."},{"key":"2078_CR50","unstructured":"Hyndman RJ, Athanasopoulos G. Forecasting: principles and practice. 2nd edition. OTexts 2021. Melbourne, Australia. OTexts.com\/fpp2. Accessed 24 Sept 2024."},{"key":"2078_CR51","unstructured":"Nau, R. Linear regression models. Statistical forecasting: notes on regression and time series analysis. Fuqua School of Business, Duke University; 2020. https:\/\/people.duke.edu\/~rnau\/rsquared.htm. Accessed 28 May 2025."},{"issue":"366","key":"2078_CR52","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2307\/2286348","volume":"74","author":"DA Dickey","year":"1979","unstructured":"Dickey DA, Fuller WA. Distribution of the estimators for autoregressive time series with a unit root. J Am Stat Assoc. 1979;74(366):427\u201331. https:\/\/doi.org\/10.2307\/2286348.","journal-title":"J Am Stat Assoc"},{"key":"2078_CR53","unstructured":"Organisation for Economic Co-operation and development (OECD). OECD Health Statistics 2024. Definitions, Sources and Methods. Total pharmaceutical consumption by DDDs. OECD; 2024. https:\/\/stats.oecd.org\/wbos\/fileview2.aspx?IDFile=6f2bfdca-6a41-4b50-9b47-b0a1a7d12a1e. Accessed 4 Apr 2025."},{"key":"2078_CR54","unstructured":"IBM. Time Series Model. IBM SPSS Modeler. IBM; 2021. https:\/\/www.ibm.com\/docs\/hr\/spss-modeler\/saas?topic=SS3RA7_sub\/modeler_mainhelp_client_ddita\/clementine\/timeseries_modelnode.htm. Accessed 29 May 2025."},{"key":"2078_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03721-4","author":"LJ Bindel","year":"2025","unstructured":"Bindel LJ, Seifert R. Long-term forecast for antibacterial drug consumption in Germany using ARIMA models. Naunyn Schmiedebergs Arch Pharmacol. 2025. https:\/\/doi.org\/10.1007\/s00210-024-03721-4.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2078_CR56","unstructured":"Our World in Data. Depressive disorders prevalence, 2021. Data source: IHME, Global Burden of Disease; 2024. https:\/\/ourworldindata.org\/grapher\/depressive-disorders-prevalence-ihme?region=Europe. Accessed 13 Apr 2025."},{"issue":"5","key":"2078_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-062197","volume":"12","author":"C Lunghi","year":"2022","unstructured":"Lunghi C, Dugas M, Leclerc J, et al. Global prevalence of antidepressant drug utilization in the community: protocol for a systematic review. BMJ Open. 2022;12(5):e062197. https:\/\/doi.org\/10.1136\/bmjopen-2022-062197.","journal-title":"BMJ Open"},{"issue":"3","key":"2078_CR58","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1192\/bjp.bp.114.156786","volume":"207","author":"D Lewer","year":"2018","unstructured":"Lewer D, O\u2019Reilly C, Mojtabai R, et al. Antidepressant use in 27 European countries: associations with sociodemographic, cultural and economic factors. Br J Psychiatry. 2018;207(3):221\u20136. https:\/\/doi.org\/10.1192\/bjp.bp.114.156786.","journal-title":"Br J Psychiatry"},{"key":"2078_CR59","unstructured":"Mikulic M. Percentage change in consumption of antidepressant drugs between 2010 and 2020 in Europe, by country. Statista. Pharmaceutical Products & Market. Survey by OECD, published by Euronews. Statista. 2025. https:\/\/www.statista.com\/statistics\/1446772\/consumption-change-of-antidepressants-in-the-last-decade-in-europe-by-country\/#:~:text=Across%20the%20analyzed%20European%20countries,108%20and%20101%20percent%2C%20respectively. Accessed 31 Mar 2025."},{"key":"2078_CR60","doi-asserted-by":"publisher","DOI":"10.1177\/11786329241282526","author":"A Peano","year":"2025","unstructured":"Peano A, Calabrese F, Pechlivanidis K, et al. International trends in antidepressant consumption: a 10-year comparative analysis (2010\u20132020). Psychiatr Q. 2025. https:\/\/doi.org\/10.1177\/11786329241282526.","journal-title":"Psychiatr Q"},{"key":"2078_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100368","volume":"17","author":"S Chen","year":"2022","unstructured":"Chen S, Ford TJ, Jones PB, et al. Prevalence, progress, and subgroup disparities in pharmacological antidepressant treatment of those who screen positive for depressive symptoms: a repetitive cross-sectional study in 19 European countries. Lancet Regional Health Eur. 2022;17:100368. https:\/\/doi.org\/10.1016\/j.lanepe.2022.100368.","journal-title":"Lancet Regional Health Eur"},{"key":"2078_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2022.114704","volume":"315","author":"L Pazzagli","year":"2022","unstructured":"Pazzagli L, Reutfors J, Lucian E, et al. Increased antidepressant use during the COVID-19 pandemic: findings from the Friuli Venezia Giulia Region, Italy, 2015\u20132020. Psychiatry Res. 2022;315:114704. https:\/\/doi.org\/10.1016\/j.psychres.2022.114704.","journal-title":"Psychiatry Res"},{"key":"2078_CR63","unstructured":"World Health Organization (WHO). COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide. News. WHO; 2022. https:\/\/www.who.int\/news\/item\/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide. Accessed 4 Apr 2025."},{"key":"2078_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00551","author":"Z Yu","year":"2020","unstructured":"Yu Z, Zhang J, Zheng Y, et al. Trends in antidepressant use and expenditure in six major cities in China from 2013 to 2018. Front Psychiatry. 2020. https:\/\/doi.org\/10.3389\/fpsyt.2020.00551.","journal-title":"Front Psychiatry"},{"key":"2078_CR65","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jad.2020.12.035","volume":"281","author":"D Moreno-Agostino","year":"2021","unstructured":"Moreno-Agostino D, Wu Y, Daskalopoulou C, et al. Global trends in the prevalence and incidence of depression: a systematic review and meta-analysis. J Affect Disord. 2021;281:235\u201343. https:\/\/doi.org\/10.1016\/j.jad.2020.12.035.","journal-title":"J Affect Disord"},{"key":"2078_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.newideapsych.2023.101010","volume":"69","author":"L Foulkes","year":"2023","unstructured":"Foulkes L, Andrews JL. Are mental health awareness efforts contributing to the rise in reported mental health problems? A call to test the prevalence inflation hypothesis. New Ideas Psychol. 2023;69:101010. https:\/\/doi.org\/10.1016\/j.newideapsych.2023.101010.","journal-title":"New Ideas Psychol"},{"key":"2078_CR67","unstructured":"Boysen G, Doonan A. Expansion of the concept of mental disorder in the DSM-5. J Mind Behav. 2014; 35:225\u2013244. https:\/\/www.researchgate.net\/publication\/289721837_Expansion_of_the_concept_of_mental_disorder_in_the_DSM-5. Accessed 29 Oct 2025."},{"key":"2078_CR68","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12888-018-1711-1","volume":"18","author":"W Zhou","year":"2018","unstructured":"Zhou W, Yu Y, Yang M, et al. Policy development and challenges of global mental health: a systematic review of published studies of national-level mental health policies. BMC Psychiatry. 2018;18:138. https:\/\/doi.org\/10.1186\/s12888-018-1711-1.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"2078_CR69","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/10398562241292202","volume":"33","author":"N Haslam","year":"2025","unstructured":"Haslam N, Tse JS. Public awareness of mental illness: mental health literacy or concept creep? Australas Psychiatry. 2025;33(1):18\u201320. https:\/\/doi.org\/10.1177\/10398562241292202.","journal-title":"Australas Psychiatry"},{"issue":"7","key":"2078_CR70","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2165\/00019053-200826070-00007","volume":"26","author":"HA Huskamp","year":"2008","unstructured":"Huskamp HA, Donohue JM, Koss C, et al. Generic entry, reformulations and promotion of SSRIs in the US. Pharmacoeconomics. 2008;26(7):603\u201316. https:\/\/doi.org\/10.2165\/00019053-200826070-00007.","journal-title":"Pharmacoeconomics"},{"key":"2078_CR71","unstructured":"Barbato A, Vallarina M, Rapisarda F et al. Access to mental health care in Europe. EU compass for action on mental health and well-being. 2016. https:\/\/health.ec.europa.eu\/system\/files\/2016-12\/ev_20161006_co04_en_0.pdf. Accessed 5 Apr 2025."},{"key":"2078_CR72","doi-asserted-by":"publisher","unstructured":"Organisation for Economic Co-operation and Devleoppment (OECD). Evaluation of Luxembourg's COVID-19 Response: Learning from the Crisis to Increase Resilience. Paris: OECD Publishing; 2022. https:\/\/doi.org\/10.1787\/2c78c89f-en","DOI":"10.1787\/2c78c89f-en"},{"issue":"4","key":"2078_CR73","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/pds.1574","volume":"17","author":"R Viola","year":"2008","unstructured":"Viola R, Benko R, Nagy G, et al. National trend of antidepressant consumption and its impact on suicide rate in Hungary. Pharmacoepidemiol Drug Saf. 2008;17(4):401\u20135. https:\/\/doi.org\/10.1002\/pds.1574.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2078_CR74","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212290","volume":"4","author":"D Santarsieri","year":"2015","unstructured":"Santarsieri D, Schwartz TL. Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs Context. 2015;4:212290. https:\/\/doi.org\/10.7573\/dic.212290.","journal-title":"Drugs Context"},{"issue":"7","key":"2078_CR75","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11096tx4c","volume":"73","author":"ME Thase","year":"2012","unstructured":"Thase ME. MAOIs and depression treatment guidelines. J Clin Psychiatry. 2012;73(7):e24. https:\/\/doi.org\/10.4088\/JCP.11096tx4c.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"2078_CR76","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/phar.1576","volume":"35","author":"SJ Thomas","year":"2015","unstructured":"Thomas SJ, Shin M, McInnis MG, et al. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression. Pharmacotherapy. 2015;35(4):433\u201349. https:\/\/doi.org\/10.1002\/phar.1576.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"2078_CR77","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/acps.13753","volume":"150","author":"TK Birkenhager","year":"2024","unstructured":"Birkenhager TK, Heijnen WT. Monoamine oxidase inhibitors: seriously underused in the treatment of major depression. Acta Psychiatr Scand. 2024;150(6):497\u20139. https:\/\/doi.org\/10.1111\/acps.13753.","journal-title":"Acta Psychiatr Scand"},{"key":"2078_CR78","unstructured":"Sub Laban T, Saadabadi A. Monoamine Oxidase Inhibitors (MAOI). Treasure Island (FL): StatPearls Publishing; 2023. Last accessed: October 28 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539848\/"},{"key":"2078_CR79","unstructured":"Hirsch M, Birnbaum RJ, Roy-Byrne PP et al. Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects. UpToDate. 2025. https:\/\/www.uptodate.com\/contents\/monoamine-oxidase-inhibitors-maois-pharmacology-administration-safety-and-side-effects#topicContent. Accessed 4 Apr2025."},{"key":"2078_CR80","unstructured":"Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. Treasure Island (FL): StatPearls Publishing; 2023. Last accessed: October 28 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554406\/"},{"key":"2078_CR81","unstructured":"National Health Service (NHS). Overview-Selective serotonin reuptake inhibitors (SSRIs). NHS; 2021. https:\/\/www.nhs.uk\/mental-health\/talking-therapies-medicine-treatments\/medicines-and-psychiatry\/ssri-antidepressants\/overview\/. Accessed 4 Apr 2025."},{"key":"2078_CR82","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/164_2018_167","volume":"250","author":"TE Schwasinger-Schmidt","year":"2019","unstructured":"Schwasinger-Schmidt TE, Macaluso M. Other Antidepressants. Handb Exp Pharmacol. 2019;250:325\u201355. https:\/\/doi.org\/10.1007\/164_2018_167.","journal-title":"Handb Exp Pharmacol"},{"issue":"5","key":"2078_CR83","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1080\/08039480801984156","volume":"62","author":"E Sigurdsson","year":"2008","unstructured":"Sigurdsson E, Olafsd\u00f3ttir T, Gottfredsson M. Public views on antidepressant treatment: lessons from a national survey. Nord J Psychiatry. 2008;62(5):374\u20138. https:\/\/doi.org\/10.1080\/08039480801984156.","journal-title":"Nord J Psychiatry"},{"key":"2078_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2013.00030","author":"A Vilhelmsson","year":"2013","unstructured":"Vilhelmsson A. Depression and antidepressants: a Nordic perspective. Front Public Health Sec Epidemiol. 2013. https:\/\/doi.org\/10.3389\/fpubh.2013.00030.","journal-title":"Front Public Health Sec Epidemiol"},{"issue":"2","key":"2078_CR85","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.healthpol.2013.03.002","volume":"111","author":"G Thengilsdottir","year":"2013","unstructured":"Thengilsdottir G, Gardarsdottis H, Almarsdottis AB, et al. The association between lifting an administrative restriction on antidepressant dispensing and treatment patterns in Iceland. Health Policy. 2013;111(2):193\u20139. https:\/\/doi.org\/10.1016\/j.healthpol.2013.03.002.","journal-title":"Health Policy"},{"key":"2078_CR86","unstructured":"Laursen M, Jensen A, Schwartson R et al. (NOMENSCO group on Medicine Statistics). Antidepressants prevalence. Nordic Health & Welfare Statistics; 2024. https:\/\/nhwstat.org\/health\/pharmaceutical-products\/prevalence\/antidepressants-prevalence. Accessed 5 Apr 2025."},{"issue":"4","key":"2078_CR87","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/08039488.2019.1707283","volume":"74","author":"J Harro","year":"2020","unstructured":"Harro J, Aadamsoo K, Rootslane L, et al. Comparison of psychotropic medication use in the Baltic countries. Nord J Psychiatry. 2020;74(4):301\u20136. https:\/\/doi.org\/10.1080\/08039488.2019.1707283.","journal-title":"Nord J Psychiatry"},{"key":"2078_CR88","unstructured":"Styraite G, Buka AA, Sarskute A et al. Depression Management in Primary Care in Lithuania and Latvia. Biol Psychiatry Psychopharmacol 2020; 22(1). https:\/\/biological-psychiatry.eu\/wpcontent\/uploads\/2020\/06\/BPP_May2020_17to23.pdf. Accessed 31 Oct 2025."},{"key":"2078_CR89","unstructured":"Depression Scorecard. Spotlight on Latvia. Depressioncare.eu 2022. 2022. https:\/\/www.depressioncare.eu\/latvia.html?utm. Accessed 5 Apr 2025."},{"key":"2078_CR90","unstructured":"China-CEE Institute. Latvia social briefing: Mental Health in Latvia: Unveiling Challenges and Charting the Path Forward. Institute of Economics at the Latvian Academy of Sciences 2023. Vol. 65, No. 3 (LVA). https:\/\/china-cee.eu\/2023\/10\/27\/latvia-social-briefing-mental-health-in-latvia-unveiling-challenges-and-charting-the-path-forward\/?utm. Accessed 31 Oct 2025."},{"issue":"22","key":"2078_CR91","doi-asserted-by":"publisher","first-page":"8612","DOI":"10.3390\/ijerph17228612","volume":"17","author":"M Estrela","year":"2020","unstructured":"Estrela M, Herdeiro MT, Ferreira PL, et al. The use of antidepressants, anxiolytics, sedatives and hypnotics in Europe: focusing on mental health care in Portugal and prescribing in older patients. Int J Environ Res Public Health. 2020;17(22):8612. https:\/\/doi.org\/10.3390\/ijerph17228612.","journal-title":"Int J Environ Res Public Health"},{"key":"2078_CR92","unstructured":"TPN\/Lusa. Increased antidepressant use \u201cnot all negative\u201d. The Portugal News. 2022. https:\/\/www.theportugalnews.com\/news\/2022-10-09\/increased-antidepressant-use-not-all-negative\/70997?utm. Accessed 5 Apr 2025."},{"issue":"3","key":"2078_CR93","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1192\/bji.2021.58","volume":"19","author":"A Malmendier-Muehlschlegel","year":"2022","unstructured":"Malmendier-Muehlschlegel A, Power NC. Mental health services in Luxembourg: an overview. BJPsych Int. 2022;19(3):72\u20134. https:\/\/doi.org\/10.1192\/bji.2021.58.","journal-title":"BJPsych Int"},{"key":"2078_CR94","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00406-021-01368-3","volume":"272","author":"G Fugger","year":"2022","unstructured":"Fugger G, Bartova L, Fabbri C, et al. The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries. Eur Arch Psychiatry Clin Neurosci. 2022;272:715\u201327. https:\/\/doi.org\/10.1007\/s00406-021-01368-3.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2078_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2025.107689","volume":"218","author":"LJ Bindel","year":"2025","unstructured":"Bindel LJ, Seifert R. Trends, prescribing patterns and projections of antiseizure drug use in Europe. Epilepsy Res. 2025;218:107689. https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107689.","journal-title":"Epilepsy Res"},{"key":"2078_CR96","doi-asserted-by":"publisher","unstructured":"Seifert R. Basic knowledge of pharmacology. 1st edition. Switzerland AG: Springer; 2019. https:\/\/doi.org\/10.1007\/978-3-030-18899-3","DOI":"10.1007\/978-3-030-18899-3"},{"key":"2078_CR97","unstructured":"World Health Organization (WHO). Defined Daily Dose (DDD). Definition and general considerations. ATC-DDD Toolkit. WHO 2025. https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/about-ddd. Accessed 25 May 2025."},{"issue":"3","key":"2078_CR98","doi-asserted-by":"publisher","first-page":"223","DOI":"10.31887\/DCNS.2018.20.3\/dnaber","volume":"20","author":"D Naber","year":"2018","unstructured":"Naber D, Bullinger M. Should antidepressants be used in minor depression? Dialogues Clin Neurosci. 2018;20(3):223\u20138. https:\/\/doi.org\/10.31887\/DCNS.2018.20.3\/dnaber.","journal-title":"Dialogues Clin Neurosci"},{"key":"2078_CR99","unstructured":"Singh HK, Saadabadi A. Sertraline. StatPearls Publishing, Treasure Island (FL); 2023. Last updated: February 13 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547689\/. Accessed 28 Oct 2025."},{"key":"2078_CR100","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jad.2022.02.001","volume":"303","author":"LF Camacho-Arteaga","year":"2022","unstructured":"Camacho-Arteaga LF, Gardasdottir H, Ibannez L, et al. Indications related to antidepressant prescribing in the Nivel-PCD database and the SIDIAP database. J Affect Disord. 2022;303:131\u20137. https:\/\/doi.org\/10.1016\/j.jad.2022.02.001.","journal-title":"J Affect Disord"},{"issue":"1","key":"2078_CR101","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2023.2479","volume":"67","author":"F Butlen-Ducuing","year":"2023","unstructured":"Butlen-Ducuing F, Haberkamp M, Aislaitner G, et al. The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers. Eur Psychiatry. 2023;67(1):e2. https:\/\/doi.org\/10.1192\/j.eurpsy.2023.2479.","journal-title":"Eur Psychiatry"},{"issue":"4","key":"2078_CR102","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00406-021-01324-1","volume":"272","author":"B Bandelow","year":"2022","unstructured":"Bandelow B, Werner AM, Kopp I, et al. The German guidelines for the treatment of anxiety disorders: first revision. Eur Arch Psychiatry Clin Neurosci. 2022;272(4):571\u201382. https:\/\/doi.org\/10.1007\/s00406-021-01324-1.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2078_CR103","unstructured":"Wertheimer AI, Santella TM. Problems using the Defined Daily Dose (DDD) as a statistical basis for drug pricing and reimbursement. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA); 2007. Last updated: 2007. https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/01\/i2023_IFPMA_DDD_2007_EN.pdf. Accessed 28 Oct 2025."},{"key":"2078_CR104","unstructured":"MedlinePlus. Commonly prescribed antidepressants and how they work. National Institute of Mental Health; 2023. https:\/\/magazine.medlineplus.gov\/article\/commonly-prescribed-antidepressants-and-how-they-work#:~:text=Different%20types%20of%20antidepressants%20affect,to%20treat%20insomnia%20and%20anxiety. Accessed 9 Apr 2025."},{"issue":"680","key":"2078_CR105","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3399\/bjgp19X701405","volume":"69","author":"T Kendrick","year":"2019","unstructured":"Kendrick T, Taylor D, Johnson CF. Which first-line antidepressant? Br J Gen Pract. 2019;69(680):114\u20135. https:\/\/doi.org\/10.3399\/bjgp19X701405.","journal-title":"Br J Gen Pract"},{"key":"2078_CR106","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1472-6963-14-42","volume":"14","author":"M Dlouhy","year":"2014","unstructured":"Dlouhy M. Mental health policy in Eastern Europe: a comparative analysis of seven mental health systems. BMC Health Serv Res. 2014;14:42. https:\/\/doi.org\/10.1186\/1472-6963-14-42.","journal-title":"BMC Health Serv Res"},{"key":"2078_CR107","unstructured":"Mitchell G, Murphy E, Bojarcz S et al. Is an EU-wide approach to the mental health crisis necessary? FEPS Policy Study. 2023. ISBN: 9782931233061. https:\/\/feps-europe.eu\/wp-content\/uploads\/2023\/03\/PS-Is-an-EU-wide-approach-to-the-mental-health-crisis-necessary.pdf. Accessed 5 Apr 2025."},{"issue":"3","key":"2078_CR108","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1177\/1559827616686051","volume":"11","author":"D Prescott","year":"2017","unstructured":"Prescott D, White ND. When is pharmacotherapy initiation beneficial in patients with depressive disorders? Am J Lifestyle Med. 2017;11(3):220\u20132. https:\/\/doi.org\/10.1177\/1559827616686051.","journal-title":"Am J Lifestyle Med"},{"issue":"2","key":"2078_CR109","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1176\/appi.focus.20150042","volume":"14","author":"BW Dunlop","year":"2016","unstructured":"Dunlop BW. Evidence-based applications of combination psychotherapy and pharmacotherapy for depression. Focus (American Psychiatric Publishing). 2016;14(2):156\u201373. https:\/\/doi.org\/10.1176\/appi.focus.20150042.","journal-title":"Focus (American Psychiatric Publishing)"},{"key":"2078_CR110","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jad.2016.01.036","volume":"194","author":"E Karyotake","year":"2016","unstructured":"Karyotake E, Smit Y, Henningsen KH, et al. Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects. J Affect Disord. 2016;194:144\u201352. https:\/\/doi.org\/10.1016\/j.jad.2016.01.036.","journal-title":"J Affect Disord"},{"issue":"6","key":"2078_CR111","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s40273-021-01040-7","volume":"39","author":"D Proudman","year":"2021","unstructured":"Proudman D, Greenberg P, Nellesen D. The growing burden of major depressive disorders (MDD): implications for researchers and policy makers. Pharmacoeconomics. 2021;39(6):619\u201325. https:\/\/doi.org\/10.1007\/s40273-021-01040-7.","journal-title":"Pharmacoeconomics"},{"key":"2078_CR112","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jpsychires.2024.07.05","volume":"178","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Jia X, Yang Y, et al. Change in the global burden of depression from 1990\u20132019 and its prediction for 2030. J Psychiatr Res. 2024;178:16\u201322. https:\/\/doi.org\/10.1016\/j.jpsychires.2024.07.05.","journal-title":"J Psychiatr Res"},{"key":"2078_CR113","doi-asserted-by":"publisher","unstructured":"Anmella G, Sanabra M, Prim\u00e9-Tous M et al. Antidepressants overuse in primary care: Prescription trends between 2010 and 2019 in Catalonia. Revista de Psiquiatr\u00eda y Salud Mental 2022. https:\/\/doi.org\/10.1016\/j.rpsm.2022.12.001","DOI":"10.1016\/j.rpsm.2022.12.001"},{"issue":"2","key":"2078_CR114","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1192\/apt.bp.107.004820","volume":"15","author":"L Palaniyappan","year":"2009","unstructured":"Palaniyappan L, Insole L, Ferrier N. Combining antidepressants: a review of evidence. Adv Psychiatr Treat. 2009;15(2):90\u20139. https:\/\/doi.org\/10.1192\/apt.bp.107.004820.","journal-title":"Adv Psychiatr Treat"},{"key":"2078_CR115","unstructured":"Rush AJ, Roy-Byrne PP, Solomon D. Unipolar depression in adults: treatment with antidepressant combinations. UpToDate 2025. 2025. https:\/\/www.uptodate.com\/contents\/unipolar-depression-in-adults-treatment-with-antidepressant-combinations#H78562923. Accessed 13 Apr 2025."},{"issue":"8","key":"2078_CR116","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00023210-200620080-00002","volume":"20","author":"J Jureidini","year":"2006","unstructured":"Jureidini J, Tonkin A. Overuse of antidepressant drugs for the treatment of depression. CNS Drugs. 2006;20(8):623\u201332. https:\/\/doi.org\/10.2165\/00023210-200620080-00002.","journal-title":"CNS Drugs"},{"issue":"4","key":"2078_CR117","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/gps.5047","volume":"34","author":"FH Boehlen","year":"2019","unstructured":"Boehlen FH, Freigofas J, Herzog W, et al. Evidence for underuse and overuse of antidepressants in older adults: results of a large population-based study. Int J Geriatr Psychiatry. 2019;34(4):539\u201347. https:\/\/doi.org\/10.1002\/gps.5047.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"11","key":"2078_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e32594","volume":"10","author":"L Francia","year":"2024","unstructured":"Francia L, De Giorgi R, Lara E, et al. Treatment coverage for depression in the general Spanish population and the impact of the Covid-19 pandemic. Heliyon. 2024;10(11):e32594. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e32594.","journal-title":"Heliyon"},{"issue":"12","key":"2078_CR119","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S2215-0366(24)00317-1","volume":"11","author":"DF Santomauro","year":"2024","unstructured":"Santomauro DF, Vos T, Whiteford HA, et al. Service coverage for major depressive disorder: estimated rates of minimally adequate treatment for 204 countries and territories in 2021. Lancet Psychiatry. 2024;11(12):1012\u201321. https:\/\/doi.org\/10.1016\/S2215-0366(24)00317-1.","journal-title":"Lancet Psychiatry"},{"key":"2078_CR120","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00210-024-03413-z","volume":"398","author":"R Seifert","year":"2025","unstructured":"Seifert R, Schirmer B, Seifert J. How pharmacology can aid in the diagnosis of mental disorders. Naunyn Schmiedebergs Arch Pharmacol. 2025;398:1099\u2013110. https:\/\/doi.org\/10.1007\/s00210-024-03413-z.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2078_CR121","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s00210-020-01918-x","volume":"393","author":"R Seifert","year":"2020","unstructured":"Seifert R, Schirmer B. A simple mechanistic terminology of psychoactive drugs: a proposal. Naunyn-Schmiedebergs Arch Pharmacol. 2020;393:1331\u20139. https:\/\/doi.org\/10.1007\/s00210-020-01918-x.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"2078_CR122","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s43045-023-00315-3","volume":"30","author":"SF Javaid","year":"2023","unstructured":"Javaid SF, Hashim IJ, Hashim MJ, et al. Epidemiology of anxiety disorders: global burden and sociodemographic associations. Middle East Curr Psychiatry. 2023;30:44. https:\/\/doi.org\/10.1186\/s43045-023-00315-3.","journal-title":"Middle East Curr Psychiatry"},{"key":"2078_CR123","unstructured":"Institute for Health Metrics and Evaluation (IHME). GBD Results. GBD 2023. University of Washington; 2025. Last updated: 2025. https:\/\/vizhub.healthdata.org\/gbd-results\/. Accessed 25 Oct 2025."},{"key":"2078_CR124","unstructured":"Barnhill JW. Overview of anxiety disorders. Anxiety and stressor-related disorders. MSD Manual, Professional Version; 2024. Last updated: January 2024. https:\/\/www.msdmanuals.com\/professional\/psychiatric-disorders\/anxiety-and-stressor-related-disorders\/overview-of-anxiety-disorders. Accessed 28 Oct 2025."},{"key":"2078_CR125","unstructured":"Centre for Addiction and Mental Health (CAMH). Depression: psychopharmacology. treating conditions and disorders. CAMH, Canada; 2019. Last updated: 2019. https:\/\/www.camh.ca\/en\/professionals\/treating-conditions-and-disorders\/depression\/depression---treatment\/depression---psychopharmacology. Accessed 28 Oct 2025."},{"key":"2078_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102507","author":"J Brandt","year":"2024","unstructured":"Brandt J, Bressi J, L\u00ea ML, et al. Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review. eClinicalMedicine. 2024. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102507.","journal-title":"eClinicalMedicine"},{"issue":"7","key":"2078_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2018.e00688","volume":"4","author":"MM Tanguay Bernard","year":"2018","unstructured":"Tanguay Bernard MM, Luc M, Carrier JD, et al. Patterns of benzodiazepines use in primary care adults with anxiety disorders. Heliyon. 2018;4(7):e00688. https:\/\/doi.org\/10.1016\/j.heliyon.2018.e00688.","journal-title":"Heliyon"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02078-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-02078-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02078-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:16:59Z","timestamp":1778746619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-02078-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":127,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2078"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-02078-9","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"Not applicable because publicly available information is used as a data source.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"This research was conducted according to the guidelines of good scientific practice of the Hannover Medical School (\n                      \n                      . The Hannover Medical School follows the guidelines of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG). No ethics approval is required because publicly available information is used as a data source.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}